Search research articles
Contact Us
Filters
Showing results (1-10 of 142) with videos related to
Page
of 15
Sort By:
Bulletin De L'Academie Nationale De Medecine
|
December 25, 2012
[Mechanisms of action of intravenous immunoglobulins]
Srini V Kaveri
Autoimmunity Reviews
|
February 22, 2012
Intravenous immunoglobulin: exploiting the potential of natural antibodies
Srini V Kaveri
Trends in Pharmacological Sciences
|
September 12, 2018
Kill 'Em All: Efgartigimod Immunotherapy for Autoimmune Diseases
Jagadeesh Bayry, Srini V Kaveri
International Immunology
|
July 2, 2017
IVIG-mediated effector functions in autoimmune and inflammatory diseases
Caroline Galeotti, Srini V Kaveri, Jagadeesh Bayry
Cell Host & Microbe
|
November 11, 2016
Tackling Difficult Staphylococcus aureus Infections: Antibodies Show the Way
Bo Shopsin, Srini V Kaveri, Jagadeesh Bayry
Clinical & Translational Immunology
|
October 22, 2020
Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19)
Caroline Galeotti, Srini V Kaveri, Jagadeesh Bayry
Trends in Molecular Medicine
|
February 15, 2015
Molecular and immunological biomarkers to predict IVIg response
Caroline Galeotti, Srini V Kaveri, Jagadeesh Bayry
Autoimmunity Reviews
|
March 8, 2011
Comparison of different IVIg preparations on IL-17 production by human Th17 cells
Mohan S Maddur, Srini V Kaveri, Jagadeesh Bayry
Trends in Pharmacological Sciences
|
May 25, 2015
IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties
Jagadeesh Bayry, Hans-Peter Hartung, Srini V Kaveri
Journal of Immunology (Baltimore, Md. : 1950)
|
January 21, 2012
Natural IgM in immune equilibrium and harnessing their therapeutic potential
Srini V Kaveri, Gregg J Silverman, Jagadeesh Bayry
Page
of 15
Search research articles
Search
Showing results (1-10 of 142) with videos related to
Sort By:
Page
of 15
Bulletin De L'Academie Nationale De Medecine
|
December 25, 2012
[Mechanisms of action of intravenous immunoglobulins]
Srini V Kaveri
Autoimmunity Reviews
|
February 22, 2012
Intravenous immunoglobulin: exploiting the potential of natural antibodies
Srini V Kaveri
Trends in Pharmacological Sciences
|
September 12, 2018
Kill 'Em All: Efgartigimod Immunotherapy for Autoimmune Diseases
Jagadeesh Bayry, Srini V Kaveri
International Immunology
|
July 2, 2017
IVIG-mediated effector functions in autoimmune and inflammatory diseases
Caroline Galeotti, Srini V Kaveri, Jagadeesh Bayry
Cell Host & Microbe
|
November 11, 2016
Tackling Difficult Staphylococcus aureus Infections: Antibodies Show the Way
Bo Shopsin, Srini V Kaveri, Jagadeesh Bayry
Clinical & Translational Immunology
|
October 22, 2020
Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19)
Caroline Galeotti, Srini V Kaveri, Jagadeesh Bayry
Trends in Molecular Medicine
|
February 15, 2015
Molecular and immunological biomarkers to predict IVIg response
Caroline Galeotti, Srini V Kaveri, Jagadeesh Bayry
Autoimmunity Reviews
|
March 8, 2011
Comparison of different IVIg preparations on IL-17 production by human Th17 cells
Mohan S Maddur, Srini V Kaveri, Jagadeesh Bayry
Trends in Pharmacological Sciences
|
May 25, 2015
IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties
Jagadeesh Bayry, Hans-Peter Hartung, Srini V Kaveri
Journal of Immunology (Baltimore, Md. : 1950)
|
January 21, 2012
Natural IgM in immune equilibrium and harnessing their therapeutic potential
Srini V Kaveri, Gregg J Silverman, Jagadeesh Bayry
Page
of 15